NCT03306069

Brief Summary

The main purpose of this study is to compare the impact of aerobic interval training intensity on exercise adherence and changes in cardiorespiratory fitness, cardiometabolic risk profile, body composition, inflammatory markers and subjective health outcomes after a 12-week intervention trial in overweight individuals at increased cardiometabolic risk.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Nov 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 27, 2017

Completed
13 days until next milestone

First Posted

Study publicly available on registry

October 10, 2017

Completed
22 days until next milestone

Study Start

First participant enrolled

November 1, 2017

Completed
2.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2020

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

April 15, 2020

Completed
Last Updated

September 14, 2020

Status Verified

September 1, 2020

Enrollment Period

2.3 years

First QC Date

September 27, 2017

Last Update Submit

September 10, 2020

Conditions

Keywords

Aerobic exerciseInterval trainingVO2maxHealth PromotionInflammationBody Composition

Outcome Measures

Primary Outcomes (1)

  • Cardiorespiratory Fitness (CRF)

    CRF will be assessed by measuring Maximum Oxygen uptake (VO2max)

    12 weeks (baseline to 12 week follow-up assessment)

Secondary Outcomes (8)

  • Metabolic Syndrome Z-Score (MetS-Z-Score)

    12 weeks (baseline to 12 week follow-up assessment)

  • Body Composition

    12 weeks (baseline to 12 week follow-up assessment)

  • Insulin sensitivity

    12 weeks (baseline to 12 week follow-up assessment)

  • Inflammation

    12 weeks (baseline to 12 week follow-up assessment)

  • Health-related quality of life

    12 weeks (baseline to 12 week follow-up assessment)

  • +3 more secondary outcomes

Study Arms (4)

Control

EXPERIMENTAL

Nutritional therapy / no exercise

Other: Control

HIIT

EXPERIMENTAL

High-intensity interval training (HIIT) at 90% heart rate maximum (HRmax) combined with Nutritional therapy

Other: HIIT

MIIT-HR

EXPERIMENTAL

Heart rate based moderate-intensity interval training (MIIT-HR) at 70% heart rate maximum (HRmax) combined with Nutritional therapy

Other: MIIT-HR

MIIT-LT

EXPERIMENTAL

Lactate threshold based moderate-intensity interval training (MIIT-LT) at 105% of lactate threshold (corresponding \~70-75% HRmax) combined with Nutritional therapy

Other: MIIT-LT

Interventions

ControlOTHER

Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks

Control
HIITOTHER

Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT). HIIT: * 2 sessions per week * 5x1 min at 80-95% HRmax * time-effort per week: \~30 min

HIIT
MIIT-HROTHER

Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR). MIIT-HR: * 2 sessions per week * 5x1 min at 65-79% HRmax * time-effort per week: \~30 min

MIIT-HR
MIIT-LTOTHER

Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT). MIIT-LT: * 2 sessions per week * session 1: 2x4 min / session 2: 5x1 min, each at 105% LT * time-effort per week: \~30 min

MIIT-LT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Body Mass Index \>/=30
  • presence of at least 2 cardiometabolic risk factors

You may not qualify if:

  • Healthy persons or patients under age
  • Overweight persons without any additional cardiometabolic risk factors
  • Pregnancy, Lactation
  • Psychological disorders, epilepsy, sever neurological disorders
  • Participation in other exercise- or nutrition studies within the last 6 months
  • acute cardiovascular disease
  • malignant disease
  • Electronic implants (defibrillator, pacemaker)
  • Persons in mental hospitals by order of authorities or jurisdiction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Medicine 1, Hector Center for Nutrition, Exercise and Sports,

Erlangen, 91052, Germany

Location

Related Publications (1)

  • Reljic D, Frenk F, Herrmann HJ, Neurath MF, Zopf Y. Low-volume high-intensity interval training improves cardiometabolic health, work ability and well-being in severely obese individuals: a randomized-controlled trial sub-study. J Transl Med. 2020 Nov 7;18(1):419. doi: 10.1186/s12967-020-02592-6.

MeSH Terms

Conditions

OverweightObesityMetabolic SyndromeInflammation

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsInsulin ResistanceHyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesPathologic Processes

Study Officials

  • Dejan Reljic, Dr.

    University Erlangen Nuremberg Medical School

    PRINCIPAL INVESTIGATOR
  • Yurdaguel Zopf, Prof.

    University Erlangen Nuremberg Medical School

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Masking Details
Outcome Assessors involved in data analysis will not be aware of the arm to which the participants were allocated (single-blinded masking).
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: Parallel Assignment parallel-group, randomized-controlled study
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 27, 2017

First Posted

October 10, 2017

Study Start

November 1, 2017

Primary Completion

February 15, 2020

Study Completion

April 15, 2020

Last Updated

September 14, 2020

Record last verified: 2020-09

Locations